| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA275462 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 2 | NIH | 10/31/2023 | $0 |
| | 2024 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 3 | NIH | 11/15/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,000,000 ) |
| | 2023 | 2023 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA275462 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 2 | NIH | 9/8/2023 | $1,000,000 |
| | 2023 | 2023 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA275462 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 001 | 2 | NIH | 9/13/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $1,000,000 ) |
| | 2022 | 2022 | ADECTO PHARMACEUTICALS INC | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA275462 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 1 | NIH | 8/17/2022 | $1,000,000 |
| | 2022 | 2019 | ADECTO PHARMACEUTICALS INC | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R43CA239942 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 1 | NIH | 5/23/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $0 ) |
| | 2021 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 3 | NIH | 7/20/2021 | $0 |
| | 2021 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R43CA239942 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 1 | NIH | 2/2/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,302,084 ) |
| | 2019 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 003 | 3 | NIH | 7/31/2019 | $2,084 |
| | 2019 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R43CA239942 | Development of a Companion Diagnostic Assay for Detection of ADAM8-Positive Cancers | 000 | 1 | NIH | 2/19/2019 | $300,000 |
| | 2019 | 2019 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 002 | 3 | NIH | 7/23/2019 | $1,000,000 |
| | 2019 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 2 | NIH | 2/13/2019 | $0 |
| | 2019 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 001 | 1 | NIH | 2/7/2019 | -$3,000 |
| | 2019 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 001 | 2 | NIH | 5/7/2019 | $42,198 |
| | 2019 | 2017 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 1 | NIH | 2/7/2019 | -$39,198 |
|
| Issue Date FY: 2018 ( Subtotal = $1,003,000 ) |
| | 2018 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 001 | 1 | NIH | 5/23/2018 | $3,000 |
| | 2018 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 005 | 1 | NIH | 8/22/2018 | $0 |
| | 2018 | 2018 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R44CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 2 | NIH | 8/29/2018 | $1,000,000 |
| | 2018 | 2017 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 004 | 1 | NIH | 8/21/2018 | $0 |
| | 2018 | 2016 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 002 | 1 | NIH | 8/16/2018 | $0 |
| | 2018 | 2016 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 1 | NIH | 4/5/2018 | $0 |
| | 2018 | 2016 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 003 | 1 | NIH | 8/20/2018 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $50,000 ) |
| | 2017 | 2017 | ADECTO PHARMACEUTICALS, INC. | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 1 | NIH | 1/12/2017 | $50,000 |
|
| Issue Date FY: 2016 ( Subtotal = $363,490 ) |
| | 2016 | 2016 | ADECTO PHARMACEUTICALS, INC | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 000 | 1 | NIH | 4/14/2016 | $300,000 |
| | 2016 | 2016 | ADECTO PHARMACEUTICALS, INC | 549 WASHINGTON ST | BROOKLINE | MA | 02446-4567 | NORFOLK | USA | R41CA200161 | Antibody targeting of ADAM8 for treatment of triple-negative breast cancer | 001 | 1 | NIH | 9/19/2016 | $63,490 |
|
|
